سعر ريتمونورم 150 مجم 30 قرص 2024

• To prolong the time to recurrence of symptomatic paroxysmal atrial fibrillation/flutter in patients without structural heart disease.Population: Adults without structural heart diseaseDailyMed (U.S. National Library of Medicine)
• To prolong the time to recurrence of symptomatic paroxysmal supraventricular tachycardia (PSVT) in patients without structural heart disease.Population: Adults without structural heart diseaseDailyMed (U.S. National Library of Medicine)
• Treatment of documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia; initiate in hospital.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>5%): unusual taste, nausea and/or vomiting, dizziness, constipation, headache, fatigue, first-degree AV block and intraventricular conduction delay.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Heart failure; cardiogenic shock; sinoatrial, AV or intraventricular conduction disorders (e.g. sick sinus syndrome, AV block) without an artificial pacemaker; known Brugada syndrome; bradycardia; marked hypotension; bronchospastic disorders or severe obstructive pulmonary disease; marked electrolyte imbalance.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning (mortality): in CAST, IC antiarrhythmics increased mortality in post-MI patients with non-life-threatening ventricular arrhythmias; consider propafenone to have significant proarrhythmic risk in structural heart disease.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• May unmask Brugada syndrome, provoke heart failure, cause conduction disturbances and affect artificial pacemakers; avoid with drugs that prolong the QT interval where possible.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CYP2D6 inhibitors combined with CYP3A4 inhibitors (e.g. ritonavir, ketoconazole, erythromycin, grapefruit juice; desipramine, paroxetine, sertraline)Increased propafenone levels and proarrhythmia risk; avoid simultaneous use of a CYP2D6 inhibitor and a CYP3A4 inhibitor.DailyMed (U.S. National Library of Medicine)
• DigoxinDigoxin exposure increased by 60-270%; monitor digoxin levels and adjust dose.DailyMed (U.S. National Library of Medicine)
• WarfarinWarfarin concentrations increased by 39% with prolonged prothrombin time; monitor INR and adjust warfarin dose.DailyMed (U.S. National Library of Medicine)

• No studies in pregnant women; decades of use have not identified drug-associated risks of miscarriage or birth defects. Propafenone crosses the placenta; monitor fetus/neonate for arrhythmias.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Propafenone and 5-OH-propafenone are present in human milk at likely low levels; weigh breastfeeding benefits against maternal need and infant risk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.